InMed Pharmaceuticals (TSX:IN,OTCQX:IMLFF) confirmed that cannabinol (CBN) is the active pharmaceutical ingredient in its two product candidates under development for for epidermolysis bullosa and glaucoma.
As quoted in the press release:
InMed is leading the way in the clinical development of CBN to treat human disease.
“We are proud to be the first company to investigate cannabinol’s therapeutic potential in human clinical trials,” commented InMed CEO, Eric A. Adams. “InMed has completed more than 30 preclinical pharmacology and toxicology studies, identifying potential therapeutic advantages of CBN in specific disease models over the more common cannabinoids THC and CBD, as well as other rare variants.” Mr. Adams continued, “We are simultaneously exploring innovative biosynthetic manufacturing methods and therapeutic applications of CBN formulations to target diseases with high unmet medical need.”